Active substance

Results for the substance risankizumab

6 results

About this active substance

Risankizumab is a monoclonal antibody used for the treatment of moderate to severe plaque psoriasis in adults. It works by inhibiting interleukin-23 (IL-23), a protein involved in inflammation, thereby reducing psoriasis symptoms.

The medication is administered as a subcutaneous injection, as directed by a doctor, usually once every few weeks. It is important for patients to follow the treatment regimen and inform the doctor of any unusual symptoms.

Patients should be aware of potential side effects, such as injection site reactions, respiratory infections, or headaches. It is important to inform the doctor of any unusual symptoms.

Common side effects include injection site reactions, respiratory infections, and headaches. In rare cases, severe reactions such as allergic reactions or serious infections may occur. Patients should be informed of these risks before administration.